Itta M Minderhoud1, Ewout W Steyerberg, Ad A van Bodegraven, C Janneke van der Woude, Daniel W Hommes, Gerard Dijkstra, Herma H Fidder, Matthijs P Schwartz, Bas Oldenburg. 1. *Department of Internal Medicine and Gastroenterology, Tergooi Hospital, Hilversum, the Netherlands; †Center for Medical Decision Making, Department of Public Health, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands; ‡Department of Gastroenterology, VU Medical Center, Amsterdam, the Netherlands; §Department of Gastroenterology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands; ‖Center for Inflammatory Bowel Diseases, UCLA Health System, Los Angeles, California; ¶Department of Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; **Department of Gastroenterology, University Medical Center Utrecht, Utrecht, the Netherlands; and ††Department of Gastroenterology, Meander Medical Center, Amersfoort, the Netherlands.
Abstract
BACKGROUND: Mucosal healing is presently considered one of the primary goals in treatment of Crohn's disease (CD), but this can only be confirmed by endoscopy. We aimed to design and validate a new disease activity index based on a combination of clinical characteristics and readily available laboratory parameters, which reliably predicts the presence and severity of endoscopic disease activity in patients with CD. METHODS: Thirteen clinical characteristics and laboratory variables were selected for analysis. Endoscopic disease activity was assessed by the Crohn's disease Endoscopic Index of Severity. A linear regression model was based on 93 ileocolonoscopies performed in 82 patients with CD and internally validated by bootstrap resampling. Subsequently, the newly developed model was validated in a cohort of 99 patients. RESULTS: The number of liquid stools during 1 day × 0.25 + C-reactive protein (in milligrams per liter) × 0.1 + platelet count (× 10(9)/L) × 0.01 + fecal calprotectin (in milligrams per liter) × 0.001 - mean platelet volume (in femtoliters) × 0.2 optimally predicted the severity of endoscopic disease activity (bootstrap adjusted R2 = 0.50). The model demonstrated good agreement in the external validation (r = 0.7), especially for (ileo)colonic CD (r = 0.8). Using receiver operator characteristic statistics, a cutoff point of 3 on the new index indicated endoscopic disease activity with a sensitivity of 80% and a specificity of 92%. CONCLUSIONS: This newly developed, noninvasive, index was found to reliably predict endoscopic disease activity in patients with CD. This tool can facilitate clinical decision making and might prove valuable in clinical trials.
BACKGROUND:Mucosal healing is presently considered one of the primary goals in treatment of Crohn's disease (CD), but this can only be confirmed by endoscopy. We aimed to design and validate a new disease activity index based on a combination of clinical characteristics and readily available laboratory parameters, which reliably predicts the presence and severity of endoscopic disease activity in patients with CD. METHODS: Thirteen clinical characteristics and laboratory variables were selected for analysis. Endoscopic disease activity was assessed by the Crohn's disease Endoscopic Index of Severity. A linear regression model was based on 93 ileocolonoscopies performed in 82 patients with CD and internally validated by bootstrap resampling. Subsequently, the newly developed model was validated in a cohort of 99 patients. RESULTS: The number of liquid stools during 1 day × 0.25 + C-reactive protein (in milligrams per liter) × 0.1 + platelet count (× 10(9)/L) × 0.01 + fecal calprotectin (in milligrams per liter) × 0.001 - mean platelet volume (in femtoliters) × 0.2 optimally predicted the severity of endoscopic disease activity (bootstrap adjusted R2 = 0.50). The model demonstrated good agreement in the external validation (r = 0.7), especially for (ileo)colonic CD (r = 0.8). Using receiver operator characteristic statistics, a cutoff point of 3 on the new index indicated endoscopic disease activity with a sensitivity of 80% and a specificity of 92%. CONCLUSIONS: This newly developed, noninvasive, index was found to reliably predict endoscopic disease activity in patients with CD. This tool can facilitate clinical decision making and might prove valuable in clinical trials.
Authors: Arno R Bourgonje; Ruben Y Gabriëls; Martin H de Borst; Marian L C Bulthuis; Klaas Nico Faber; Harry van Goor; Gerard Dijkstra Journal: Antioxidants (Basel) Date: 2019-09-01
Authors: Arno R Bourgonje; Julius Z H von Martels; Ruben Y Gabriëls; Tjasso Blokzijl; Manon Buist-Homan; Janette Heegsma; Bernadien H Jansen; Hendrik M van Dullemen; Eleonora A M Festen; Rinze W F Ter Steege; Marijn C Visschedijk; Rinse K Weersma; Paul de Vos; Klaas Nico Faber; Gerard Dijkstra Journal: Front Med (Lausanne) Date: 2019-11-05
Authors: Stephan R Vavricka; Henriette Heinrich; Simon Buetikofer; Flavia Breitenmoser; Emanuel Burri; Xiaoye Schneider-Yin; Jasmin Barman-Aksoezen; Luc Biedermann; Michael Scharl; Jonas Zeitz; Gerhard Rogler; Benjamin Misselwitz; Matthias Sauter Journal: United European Gastroenterol J Date: 2018-05-28 Impact factor: 4.623
Authors: Peter C Ambe; Daniel Gödde; Lars Bönicke; Marios Papadakis; Stephan Störkel; Hubert Zirngibl Journal: J Transl Med Date: 2016-04-27 Impact factor: 5.531